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Abstract
Background: Polymorphisms in DNA repair genes have been associated to repair DNA lesions, and might
contribute to the individual susceptibility to develop different types of cancer. Nucleotide excision repair (NER),
base excision repair (BER), and double-strand break repair (DSBR) are the main DNA repair pathways. We
investigated the relationship between polymorphisms in two NER genes, XPC (poly (AT) insertion/deletion: PAT-
/+) and XPD (Asp312Asn and Lys751Gln), the BER gene XRCC1 (Arg399Gln), and the DSBR gene XRCC3
(Thr241Met) and the risk of developing lung cancer.
Methods: A hospital-based case-control study was designed with 516 lung cancer patients and 533 control
subjects, matched on ethnicity, age, and gender. Genotypes were determined by PCR-RFLP and the results were
analysed using multivariate unconditional logistic regression, adjusting for age, gender and pack-years.
Results: Borderline association was found for XPC and XPD NER genes polymorphisms, while no association was
observed for polymorphisms in BER and DSBR genes. XPC PAT+/+ genotype was associated with no statistically
significant increased risk among ever smokers (OR = 1.40; 95%CI = 0.94–2.08), squamous cell carcinoma (OR =
1.44; 95%CI = 0.85–2.44), and adenocarcinoma (OR = 1.72; 95%CI = 0.97–3.04). XPD variant genotypes (312Asn/
Asn and 751Gln/Gln) presented a not statistically significant risk of developing lung cancer (OR = 1.52; 95%CI =
0.91–2.51; OR = 1.38; 95%CI = 0.85–2.25, respectively), especially among ever smokers (OR = 1.58; 95%CI =
0.96–2.60), heavy smokers (OR = 2.07; 95%CI = 0.74–5.75), and adenocarcinoma (OR = 1.88; 95%CI = 0.97–
3.63). On the other hand, individuals homozygous for the XRCC1 399Gln allele presented no risk of developing
lung cancer (OR = 0.87; 95%CI = 0.57–1.31) except for individuals carriers of 399Gln/Gln genotype and without
family history of cancer (OR = 0.57; 95%CI = 0.33–0.98) and no association was found between XRCC3
Thr241Met polymorphism and lung cancer risk (OR = 0.92; 95%CI = 0.56–1.50), except for the 241Met/Met
genotype and squamous cell carcinoma risk (OR = 0.47; 95%CI = 0.23–1.00).
Conclusion: In conclusion, we analysed the association between XPC, XPD, XRCC1, and XRCC3 polymorphisms
and the individual susceptibility to develop lung cancer in the Spanish population, specifically with a highly tobacco
exposed population. We attempt to contribute to the discovery of which biomarkers of DNA repair capacity are
useful for screening this high-risk population for primary preventing and early detection of lung cancer.
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Background
Lung cancer is the most common cancer in the world, in
2002 there were 1.35 million new cases, representing
12.4% of total cancers. It was also the most common
cause of death from cancer, with 1.18 million global
deaths, representing 17.6% of the total deaths from can-
cer. Almost half (49.9%) of the cases occur in the develop-
ing countries of the world [1]. In Spain, lung cancer is the
main cancer in men, accounting for 16,628 deaths in
2004 [2].
Although cigarette smoking is the major cause of lung can-
cer, only a small fraction of smokers develop this disease,
suggesting that other causes, including genetic susceptibil-
ity, might contribute to the variation in individual lung
cancer risk [3,4]. This genetic susceptibility may result
from inherited polymorphisms in the genes involved in
carcinogen metabolism and DNA damage repair [5-7].
DNA repair systems play a critical role protecting the
genome from insults caused by carcinogenic agents, such
as those found in tobacco smoke [8]. Until now, more
than a hundred proteins implicated in DNA repair have
been found in human cells. These proteins are implicated
in four major DNA repair pathways, including nucleotide
excision repair (NER), base excision repair (BER), double-
strand break repair (DSBR) and mismatch repair (MMR)
[9,10].
Polymorphisms affecting the coding sequence of a gene
are very common in the population, and many of them
result in changes that alter protein function [11]. In this
sense, the completion of the human genome sequence has
allowed the identification of numerous polymorphisms
in DNA repair genes, and many of them have been shown
to contribute to genetic instability and error accumulation
due to reduced protein activity. The gene encoding the
NER protein XPC constitutes an excellent example,
because a relationship between polymorphism and
altered gene function has been established.
In a previous report, we have shown that individuals
homozygous for the XPC  PAT polymorphism have an
increased risk of developing lung cancer [12]. Neverthe-
less, PAT polymorphism in the XPC gene has been associ-
ated with an increased risk of developing different types of
cancer, including smoking-related cancers [13-15] or
melanoma [16]. Polymorphisms in other DNA repair
NER genes have also been associated with individual sus-
ceptibility to develop cancer, including the gene encoding
XPD. The presence of the variant alleles 312Asn  and
751Gln of XPD have been associated with relatively high
risk of lung cancer in Caucasian [17-20] and Asian [21-24]
populations and a recent meta-analysis concludes that the
variant genotypes 312Asn/Asn and 751Gln/Gln are associ-
ated with a statistically significant lung cancer risk in the
Caucasian population [25]. Moreover, several studies
have carried out combined analysis between lung cancer
risk and polymorphisms in different NER genes including
XPC and XPD [19,26]. Functional studies in humans have
shown that common polymorphisms in NER genes can
modify the capacity to repair DNA [27-29], and epidemi-
ologic studies have supported their role in the pathogene-
sis of smoking-related cancers [7,30].
BER genes play a key role by removing DNA damage from
oxidation, deamination, and ring fragmentation [31] and
exposure to tobacco smoking induces oxidative damage
by generation of reactive oxygen species (ROS) [32].
Therefore, polymorphisms in BER genes may be associ-
ated with lung cancer. The association between the
XRCC1 Arg399Gln polymorphism, resulting from a gua-
nine to adenine nucleotide change, and lung cancer risk
has been evaluated in a number of epidemiological stud-
ies [19,20,33-39]. A recent meta-analysis including 7385
cases and 9381 controls showed that 399Gln/Gln geno-
type was associated with an increased risk of lung cancer
among Asians but not among Caucasians [37]. A multi-
center study conducted in Europe concluded that this pol-
ymorphism was not associated with lung cancer risk [34].
Finally, DSBR pathway is the responsible for repairing
double-strand breaks. These result from exogenous agents
such as ionizing radiation or environmental carcinogens,
including those present in tobacco smoke and from
endogenously generated ROS. They can also be produced
when DNA replication encounter DNA single-strand
breaks or other types of lesion [40]. XRCC3, which partic-
ipates in DNA double-strand break via homologous
recombinational repair, presents a non-conservative
Thr241Met substitution in exon 7. Until now, there are
several conflicting reports on the association between this
polymorphism and lung cancer risk in the Caucasian pop-
ulation [19,20,38,41-43].
In order to examine if genetic polymorphisms in DNA
repair genes implicated in NER, BER and DSBR pathways
are associated with lung cancer risk, we have studied five
polymorphisms in four genes (XPC, XPD,  XRCC1,
XRCC3) in 516 cases and 533 controls of a Caucasian
population of Northern Spain, historically highly exposed
to tobacco.
Methods
Study population
The CAPUA study (Cáncer de Pulmón en Asturias) is a
hospital-based case-control study conducted in the "Uni-
dad de Epidemiología Molecular del Cáncer, Instituto
Universitario de Oncología" of Universidad de Oviedo.
Patients were recruited in two main hospitals following an
identical protocol from October 2000 to April 2005. Eligi-BMC Cancer 2007, 7:162 http://www.biomedcentral.com/1471-2407/7/162
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ble cases were incident cases of histologically confirmed
lung cancer between 30 and 85 years of age and residents
in the geographical area of each participating hospital for
at least six months before diagnosis. Patients with primary
cancer other than lung cancer occurring in the last 5 years
were excluded. Controls were selected from patients
admitted to participating hospitals for diagnoses believed
to be unrelated to the exposures of interest, individually
matched to the cases on ethnicity, gender and age (± 5
years). The main specific pathologies of the final controls
selected were: 41.1% inguinal and abdominal hernias
(ICD-9: 550–553), 32.5% injuries (ICD-9: 800–848,
860–869, 880–897), 8.8% appendicitis (ICD-9: 540), and
13.3% intestinal obstructions (ICD-9: 560, 569, 574). The
study was approved by the ethical committee of the hos-
pitals, and written consent was obtained from each partic-
ipant.
Data collection
Information on known or potential risk factors for lung
cancer was collected personally through computer-
assisted questionnaires by trained interviewers during the
first hospital admission for diagnosis. Structured ques-
tionnaires collected information on sociodemographic
characteristics, recent and prior tobacco use, environmen-
tal exposure (air pollution, environmental tobacco smok-
ing (ETS)), diet, personal and family history of cancer,
and occupational history from each participant. A total of
93.8% eligible cases and 98.5% of eligible controls agreed
to participate in the study and were interviewed. Of the
759 cases and 593 controls interviewed, 741 (97.6%)
cases and 556 (93.8%) controls provided a blood or buc-
cal cell sample for DNA extraction. Seventeen individuals
(five cases and twelve controls) were excluded because of
low amounts of DNA. 37 individuals (twenty six cases and
eleven controls) with missing information in the ques-
tionnaires and 194 cases without matched controls were
also excluded from the analyses. Thus, the final study pop-
ulation available for analysis was 516 cases and 533 con-
trols, all of whom were Caucasian.
Tobacco exposure information
Participants were defined as never smokers if they had not
smoked >100 cigarettes in their lifetime and ever smokers
otherwise. Ever smokers were further classified as current
smokers if they had smoked at least one cigarette per day
for 6 months or longer. Individuals who had smoked reg-
ularly but who had stopped smoking at least 1 year before
the interview were defined as former smokers. ETS expo-
sure was quantified determining the source, intensity, and
duration of exposure during childhood and adulthood
[44]. Smoking intensity (pack-years, PY) was defined as
the number of packs of cigarettes smoked per day multi-
plied by the number of years smoking. We categorized the
subjects as light (≤ 16.45 PY), moderate (> 16.45–53 PY),
or heavy (> 53 PY) smokers based on the quartiles of
cumulative tobacco consumption among the control
group.
Genotype analysis
Laboratory personnel were blinded to case and control
status. Genomic DNA was extracted from peripheral
blood samples (96.5% of total) or exfoliated buccal cells
(3.5% of total) as previously described [45]. For quality
control, genotyping was repeated randomly in at least 5%
of the samples, and two of the authors independently
reviewed all results. A quality control of 50 blood and
mouthwash samples from the same participants ensured
the reliability of genotyping results of mouthwash sam-
ples. In both quality controls no differences were found.
Polymorphisms studied are shown in Table 1. To deter-
mine the XPC PAT polymorphism, intron 9 of the XPC
gene was amplified by polymerase chain reaction (PCR)
using the oligonucleotides shown in Table 2 (primers and
conditions were previously described [12]). The polymor-
phisms in XPD  exon 10 (rs1799793), XPD  exon 23
(rs13181),  XRCC1  (rs25487) and XRCC3  (rs861539)
were analysed by PCR combined with restriction fragment
length polymorphism (RFLP). Details of PCR primers and
cycle conditions used are shown in Table 2. In the case of
the XRCC3 gene, the reverse primer was specially designed
to introduce the recognition site of the restriction enzyme
NcoI by replacing a G with a C (lower case). PCR was per-
formed in a 10 µl mixture containing 20 ng of genomic
DNA, 0.25 mM each dNTP, 0.5 units of Taq polymerase
(Biotools), and 10 pmol of each primer in 1 × PCR buffer.
For the amplification of XPD exon 10, dimethylsulfoxide
was added to the reaction at a final concentration of 3%.
PCR products were digested overnight with the indicated
restriction enzyme at 37°C. DNA fragments were resolved
on agarose gels and stained with ethidium bromide
(restriction enzyme and fragments sizes are shown in
Table 1). To verify that the data obtained by RFLP was
coincident with the allele sequence, representative frag-
ments were further purified for PCR-directed sequencing
to confirm the different polymorphisms (data not
shown).
Statistical analysis
Tests for Hardy-Weinberg equilibrium among controls
were conducted using observed genotype frequencies and
a χ2 test with one degree of freedom. Univariate analysis
was first performed to compare the distribution of age and
gender and the frequencies of alleles and genotypes. The
differences in the distribution between cases and controls
were tested using the χ2, Fisher exact, and Mann-Whitney
U-test, where appropriate. The crude odd ratios (ORs)
were calculated by Wolf's method [46]. Multivariate
unconditional logistic regression analysis with adjust-
ment for age, gender, and pack-years was performed toBMC Cancer 2007, 7:162 http://www.biomedcentral.com/1471-2407/7/162
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calculate adjusted ORs and 95% confidence intervals
(CIs). Gene-gene and gene-environment interactions were
estimated by the logistic regression model, which
included an interaction term as well as variables for expo-
sure (smoking), genotypes (XPC, XPD, XRCC1 or XRCC3)
and potential confounders (age and gender). All statistical
analyses were performed with STATA version 8 software.
The sample size of our study for an allele frequency
between 29–32% is enough to detect ORs greater than
1.38 with more than 90% power assuming a log-additive
model. For allele frequencies of 40%, the power to detect
an OR of 1.28 is 79%. For allele frequencies between 30–
40% as observed for polymorphisms analysed in this
study, the power to detect an OR greater than 2.00 for the
interaction gen-gen is more than 90%. Allele frequencies
of controls were calculated using following formula
(example genotypes AA, AB, BB): Allele B frequency =
[number genotypes AB + 2 × (number genotypes BB)]/[2
× (number genotypes AA + number genotypes AB +
number genotypes BB)].
Results
Subject characteristics
The analysis included 516 lung cancer cases and 533 con-
trols from the Caucasian population of Asturias, Northern
Spain. The distributions of age, gender, smoking history,
family history of cancer, and histological type for the cases
among the study subjects are summarized in Table 3.
There were no statistically significant differences among
cases and controls in terms of mean age and gender distri-
butions, suggesting that the frequency matching was ade-
quate. There is only a never smoker case of lung cancer
without ETS exposure and there were more current smok-
Table 1: Details of RFLPs studied and fragments sizes
Repair Gene exon/intron Enzyme Polymorphis
m*
Genotype Fragment 
sizes (bp)
NER XPC intron 9 - insertion 83 pb - PAT -/-
PAT +/+
266
344
XPD exon 10 StyI G23591A
(rs 1799793)
Asp312Asn Asp/Asp
Asn/Asn
244+507
33+244+474
XPD exon 23 PstI A35931C
(rs 13181)
Lys751Gln Lys/Lys
Gln/Gln
146+290
63+146+227
BER XRCC1e x o n  1 0 MspI G28152A
(rs 25487)
Arg399Gln Arg/Arg
Gln/Gln
132+278+461
278+593
DSBR XRCC3 exon 7 NcoI C18067T
(rs 861539)
Thr241Met Thr/Thr
Met/Met
136
39+97
* Reference SNP accession numbers are indicated for each polymorphism
Table 2: Details of PCR conditions for polymorphism analysis
Product Primer sequence Size (bp) PCR Conditions
XPC (PAT) (F) TAG CAC CCA GCA GTC 
AAA G
(R) TGT GAA TGT GCT TAA 
TGC TG
266/344 30 cycles: 94°C 30s, 58°C 30s, 
72°C 30s
XPD exon 10 (F) CTG TTG GTG GGT GCC 
CGT ATC TGT TGG TCT
(R) TAA TAT CGG GGC TCA 
CCC TGC AGC ACT TCC T
751 40 cycles: 94°C 30s, 65°C 30s, 
72°C 1 min
XPD exon 23 (F) GCC CGC TCT GGA TTA 
TAC G
(R) CTA TCA TCT CCT GGC 
CCC C
436 30 cycles: 94°C 30s, 64°C 30s, 
72°C 45s
XRCC1 (F) CAG TGG TGC TAA CCT 
AAT C
(R) AGT AGT CTG CTG GCT 
CTG G
871 30 cycles: 94°C 30s, 64°C 30s, 
72°C 1 min
XRCC3 (F) GCC TGG TGG TCA TCG 
ACT C
(R) CAG GGC TCT GGA AGG 
CAC TGC TCA GCT CAC GCA 
cC
136 30 cycles: 94°C 30s, 65°C 30s, 
72°C 1 minBMC Cancer 2007, 7:162 http://www.biomedcentral.com/1471-2407/7/162
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ers (53.2% vs. 39.9%) and more heavy smokers (62.85 vs.
40.41 number of pack-years, PY) in the study cases than in
the control group (P < 0.001). There is a statistically sig-
nificant difference between cases and controls regarding
type of tobacco smoked, 75.3% of cases were smokers of
black tobacco (black smokers), exclusively. Histologically,
squamous cell carcinoma (40.3%) and adenocarcinoma
(29.5%) are the main types of lung cancer presented.
We have determined the frequency of 5 polymorphisms
in 4 different genes implicated in DNA damage repair
(XPC  PAT,  XPD  Asp312Asn,  XPD  Lys751Gln,  XRCC1
Arg399Gln, and XRCC3  Thr241Met) in lung cancer
patients and matched controls in order to evaluate their
association with the risk of lung cancer. The genotype dis-
tribution for all the SNPs studied was consistent with
Hardy-Weinberg equilibrium. In the multivariate logistic
regression model, there was no evidence for any interac-
tion between variant genotypes and smoking (data not
shown).
Analysis of the XPC PAT genotype
The frequency of the XPC PAT+ allele was 0.431 in study
cases and 0.401 in controls. The frequency of the PAT+/+
genotype was higher in the study cases (19.6%) than in
controls (15.8%), although not significantly (P = 0.260)
(Table 4). When we analysed the association between XPC
genotypes and lung cancer risk, we found that those indi-
viduals homozygous for the PAT+ allele presented a not
statistically significant higher risk of lung cancer (adjusted
OR = 1.28; 95% CI = 0.85–1.92, P = 0.229).
Stratified analysis for smoking status showed that the XPC
PAT+/+ genotype was associated with a not statistically
significant increased risk among ever smokers (adjusted
OR = 1.40; 95% CI = 0.94–2.08, P = 0.100) and heavy
black smokers (adjusted OR = 1.55; 95% CI = 0.62–3.87,
P = 0.350) and stratification for histological type revealed
that the variant PAT+/+ genotype was associated with a
not statistically significant increased risk of developing
squamous cell carcinoma (adjusted OR = 1.44; 95% CI =
0.85–2.44, P = 0.175) and adenocarcinoma (adjusted OR
= 1.72; 95% CI = 0.97–3.04, P = 0.064) [see Additional
file 1].
Analysis of the Asp312Asn and Lys751Gln polymorphisms 
in the XPD gene
Analysis of the two most common polymorphisms in the
XPD gene, Asp312Asn in exon 10 and Lys751Gln in exon
23, revealed that the two polymorphisms were in linkage
disequilibrium with 20% of discrepancies, which is in
agreement with previous reports [17,18,47,48]. Due to
this linkage between both polymorphisms, the OR
observed for each allele, either global or stratified, were
very similar. The frequencies of the 312Asn and 751Gln
alleles were 0.321 and 0.340 among study cases and 0.296
and 0.319 among controls, respectively. Genotype distri-
bution and calculated ORs were very similar for both pol-
ymorphisms (Table 4), although a higher risk was
observed for the Asp312Asn polymorphism. Those indi-
viduals homozygous for the XPD  polymorphisms
(312Asn/Asn and 751Gln/Gln) presented a not statistically
significant higher risk of developing lung cancer (adjusted
OR = 1.52; 95% CI = 0.91–2.51, P = 0.106; adjusted OR =
1.38; 95% CI = 0.85–2.25, P = 0.193, respectively).
Stratified analysis showed that the 312Asn/Asn genotype
was associated with a not statistically significant increased
risk among ever smokers (adjusted OR = 1.58; 95% CI =
0.96–2.60, P = 0.074) and heavy smokers (adjusted OR =
2.07; 95% CI = 0.74–5.75, P = 0.165), as well as with an
increased risk of developing adenocarcinoma (adjusted
OR = 1.88; 95% CI = 0.97–3.63, P = 0.061) [see Addi-
tional file 2].
Analysis of the Arg399Gln polymorphism in the XRCC1 
gene
The frequency of the XRCC1 399Gln allele was 0.358 in
study cases and 0.373 in controls. The frequency of the
Gln/Gln genotype was lower in the study cases (14.5%)
than in controls (15.4%), although this was not statisti-
cally significant (P = 0.744). Individuals homozygous for
the 399Gln allele presented no risk of developing lung
cancer (adjusted OR = 0.87; 95% CI = 0.57–1.31, P =
0.500) (Table 4). Stratified analysis for selected variables
confirmed the absence of association except for individu-
als carriers of 399Gln/Gln genotype and without family
history of cancer (adjusted OR = 0.57; 95% CI = 0.33–
0.98, P = 0.042), which showed a statistically significant
protective effect. This genotype was also associated with a
not statistically significant increased risk among light
smokers (adjusted OR = 1.62; 95% CI = 0.47–5.56, P =
0.444), but decreased risk for moderate smokers (adjusted
OR = 0.67; 95% CI = 0.36–1.24, P = 0.203) [see Addi-
tional file 3].
Analysis of the Thr241Met polymorphism in the XRCC3 
gene
The frequency of the XRCC3 241Met allele was 0.354 in
study cases and 0.364 in controls. The frequency of the
241Met/Met genotype in XRCC3 was similar in the study
cases (12.4%) and in controls (13.8%), and no associa-
tion was found between XRCC3  Thr241Met polymor-
phism and lung cancer risk (adjusted OR = 0.92; 95% CI
= 0.56–1.50, P = 0.898) (Table 4). Stratified analysis for
selected variables confirmed the absence of association
except for the 241Met/Met genotype and squamous cell
carcinoma risk (adjusted OR = 0.47; 95% CI = 0.23–1.00,
P = 0.049) showing a protective effect [see Additional file
4].BMC Cancer 2007, 7:162 http://www.biomedcentral.com/1471-2407/7/162
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Combined analysis of polymorphisms in DNA repair genes 
and lung cancer
Finally, in order to test whether individual polymor-
phisms in DNA repair genes might interact and modify
the risk of developing lung cancer, ORs were estimated for
each pair of the studied polymorphisms (XPC PAT, XPD
Asp312Asn,  XPD  Lys751Gln,  XRCC1  Arg399Gln and
XRCC3  Thr241Met). Our results show an interaction
between XPC/XPD, XPC/XRCC3 and XPD/XRCC3 poly-
morphisms (Table 5). In fact, individuals with genotypes
XPC PAT(+/+)/XPD 751Lys/Gln or  XPC PAT(+/+)/XPD
751Gln/Gln  showed a 1.63-fold (CI = 0.89–2.98), P  =
0.111, and 2.25-fold (CI = 0.83–6.13), P = 0.202, higher
risk of lung cancer, respectively, when compared with
homozygous carriers of the wild type allele of both poly-
morphisms (XPC PAT(-/-)/XPD 751Lys/Lys). Furthermore,
despite the fact that the polymorphism in XRCC3 didn't
alter the overall risk of developing lung cancer when stud-
ied independently, when this polymorphism was com-
bined with those studied in XPC or XPD, we observed an
interaction between these polymorphisms. Individuals
with the XPC PAT(+/+)/XRCC3 241Met/Met or  XPD
751Gln/Gln/XRCC3 241Met/Met genotypes showed a not
significant higher risk of developing lung cancer 3.06 (CI
= 0.91–10.30) (P = 0.071) and 2.66 (CI = 0.74–9.62) (P =
0.135) respectively.
Discussion
In this study, we have examined whether polymorphisms
in four DNA repair genes involved in the nucleotide exci-
sion (NER), base excision (BER), and double-strand break
(DSBR) DNA repair pathways are implicated in the devel-
opment of lung cancer in a Caucasian population from
Asturias, Northern Spain. Our results support that poly-
morphisms in two different NER genes (XPC and XPD)
increased the risk of developing lung cancer, so individu-
Table 3: Characteristics of lung cancer cases and control patients in a Spanish population
Variable Cases (n = 516) n (%) Controls (n = 533) n (%) Pa
Gender
Male 456 (88.4) 460 (86.3)
Female 60 (11.6) 73 (13.7) 0.314
Age (yrs), mean (SD) 64.79 (10.99) 63.54 (11.33) 0.090
Smoking Status
Never 1 (0.2) 4 (0.7)
ETS exposed 35 (6.8) 141 (26.45)
Ever 480 (93.0) 388 (73.0) < 0.001
Former 222 (46.8) 224 (60.1)
Current 252 (53.2) 149 (39.9) < 0.001
Type of tobacco
Only black 359 (75.3) 223 (60.6)
Only blond 47 (9.8) 84 (22.8)
Both 71 (14.9) 61 (16.6) < 0.001
Pack-yearsb, mean (SD) 62.85 (36.18) 40.41 (38.95) < 0.001
Family history of cancer
No 272 (57.3) 317 (62.2)
Lung cancer 57 (12.0) 35 (6.9)
Other cancer 146 (30.7) 158 (31.0) 0.019
Histological type
Squamous cell carcinoma 208 (40.3)
Adenocarcinoma 152 (29.5)
Small cell carcinoma 83 (16.1)
Large cell carcinoma 16 (3.1)
Non-differentiated 39 (7.6)
Others 7 (1.3)
Clinical diagnosis 2 (0.4)
Missing 9 (1.7)
a Two-sided χ2 test and Mann-Whitney where appropriate
b Pack-years for ever smokersBMC Cancer 2007, 7:162 http://www.biomedcentral.com/1471-2407/7/162
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als homozygous for the XPC PAT+, XPD 312Asn or XPD
751Gln alleles have a higher risk of developing lung can-
cer (ORs 1.28, 1.52 and 1.38, respectively). This associa-
tion was particularly important for ever smokers and
patients with adenocarcinomas. On the other hand, no
association was found between two genes that participate
in the BER and DSBR repair processes (XRCC1  and
XRCC3) and the risk of lung cancer. Additionally, interac-
tion between XPC and XPD polymorphisms showed an
increased risk of lung cancer (OR = 2.25). Similarly, inter-
actions between XPC/XRCC3  and  XPD/XRCC3  were
observed, suggesting that coordination between both
repair systems might contribute to the individual suscep-
tibility to develop cancer.
Our study has several strengths, including high participa-
tion of eligible cases (rate 93.8%), quite large sample size
from a homogeneous population of same ancestors (516
cases and 533 controls) and the fact that all our control
subjects were under Hardy-Weinberg equilibrium. Never-
theless all our cases were pathology confirmed and finally
we applied a severe quality control from genotyping. The
main limitations of our study were hospital-based sub-
jects, recall bias due to the fact that information on smok-
ing exposure was obtained retrospectively, and especially
possible false positive associations, due to multiple com-
parisons made, we cannot exclude the possibility that
some of these associations may represent chance finding,
because the power to detect interactions was limited. On
the other hand, we have to bear in mind that 26% of con-
trols were ETS exposed which could lead to underestimate
our results. To limit selection bias, we carefully selected
controls from patients admitted for various diagnoses that
were thought to be unrelated to exposures of interest.
Nevertheless, a recent paper from Campbell et al. [49]
reported that European populations may display various
levels of genetic substructure which may lead to false pos-
itive associations due to population stratification. In our
study, we controlled for this possibility by matching indi-
viduals on the basis of European ancestry.
We have previously shown that the PAT+ allele is in com-
plete linkage disequilibrium with the intron 11 A-allele
[12], reflecting the XPC  haplotype (PAT+/939Gln/intron
11 A) with a reduced ability to repair DNA lesions and an
increased risk of developing lung cancer. Previous func-
Table 4: Analysis of polymorphisms and lung cancer risk estimates
Repair Gen SNP Genotype Cases n (%) Controls n 
(%)
Adjusteda 
OR [95% 
IC]
P P trend
NER XPC PAT -/- 172 (33.3) 190 (35.6) Reference
+/- 243 (47.1) 259 (48.6) 1.08 [0.79–
1.47]
0.627
+/+ 101 (19.6) 84 (15.8) 1.28 [0.85–
1.92]
0.229 0.246
XPD Asp312Asn Asp/Asp 240 (46.5) 260 (48.8) Reference
Asp/Asn 221 (42.8) 230 (43.1) 1.01 [0.76–
1.35]
0.934
Asn/Asn 55 (10.7) 43 (8.1) 1.52 [0.91–
2.51]
0.106 0.232
Lys751Gln Lys/Lys 222 (43.0) 243 (45.6) Reference
Lys/Gln 237 (45.9) 240 (45.0) 1.12 [0.84–
1.50]
0.437
Gln/Gln 57 (11.1) 50 (9.4) 1.38 [0.85–
2.25]
0.193 0.181
BER XRCC1 Arg399Gln Arg/Arg 222 (43.0) 217 (40.7) Reference
Arg/Gln 219 (42.5) 234 (43.9) 0.86 [0.63–
1.16]
0.320
Gln/Gln 75 (14.5) 82 (15.4) 0.87 [0.57–
1.31]
0.500 0.672
DSBR XRCC3 Thr241Met Thr/Thr 168 (41.7) 178 (41.0) Reference
Thr/Met 185 (45.9) 196 (45.2) 1.06 [0.76–
1.49]
0.724
Met/Met 50 (12.4) 60 (13.8) 0.92 [0.56–
1.50]
0.898 0.898
a Adjusted by age, gender and cumulative tobacco consumption (in pack-years: ≤ 16.45, > 16.45–53 and > 53)BMC Cancer 2007, 7:162 http://www.biomedcentral.com/1471-2407/7/162
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tional analysis has shown that cells with the A/A genotype
at the splice acceptor site in intron 11 have a higher fre-
quency of deletion of exon 12 [50], suggesting that this
mechanism might contribute to the reduced ability of
individuals with this genotype to repair DNA lesions.
Nevertheless, the effect of the Lys939Gln polymorphism
on the biochemical activity of XPC is still under investiga-
tion.
Several reports have shown that polymorphisms in the
XPC  gene increase the risk of different tumor types,
including smoking-related cancers and cutaneous
melanoma [13-16,51,52]. For lung cancer, the number of
studies is still very limited. A recent study carried out in an
Asiatic population of 432 cases and 432 controls was una-
ble to find any association between the XPC PAT polymor-
phism and the risk of developing lung cancer [53].
However, other reports studying the exon 15 polymor-
phism in Danish and Chinese populations have found an
increased risk for developing lung cancer for the 939Gln
allele [26,54], similar to our results.
The 312Asn and 751Gln alleles in the XPD gene have been
associated with a reduced capacity to repair BPDE and UV-
induced damage in host cell reactivation assays [48,55,56]
and with a higher DNA adduct, chromosomal aberra-
tions, and single-strand breaks level which is interpreted
as lower repair efficiency [27,28,57-59]. Our results con-
firm an association between these polymorphisms and
the risk of developing lung cancer, and extend previous
findings [17-22,24,25,60].
Our results for the stratified analysis are supported by bio-
logical evidence. Tobacco smoke increases the risk of lung
cancer and increases the risk for all histological types of
this cancer, including adenocarcinoma [61]. Our results
showed higher risk for adenocarcinoma, although the rea-
son for the observed histology-dependent difference in
the genetic effect conferred by these polymorphisms is
unknown, being perhaps a bit too hypothetical, it may be
attributable to differences in the carcinogenesis pathways
among the histological types of lung cancer. Various lines
of evidence have suggested that the histological type of
lung cancer may be determined by the particular initiating
agent to which an individual is exposed [62,63], which
need to be verified in further studies. Therefore, genetic
factors involved in susceptibility could be different
between the histological subtypes of lung cancer
[21,24,53].
Contrary to the results observed with polymorphisms in
genes that participate in the NER mechanism, the poly-
morphisms studied in XRCC1 and XRCC3, implicated in
other DNA repair processes such as BER and DSBR, were
not associated to the global individual susceptibility to
develop lung cancer. Previous studies of XRCC1
Arg399Gln polymorphism have shown contradictory
results, several reports have found association with differ-
ent types of cancer, including colorectal, breast, lung or
melanoma [64-70], while other reports have failed to find
association with some of these pathologies, or even found
a protective effect [71-73]. Our data showed no associa-
tion between XRCC1 Arg399Gln and lung cancer risk, but
Table 5: Combined analysis for XPC, XPD and XRCC3 polymorphisms and lung cancer risk estimates
Genotype 1 Genotype 2 Cases n(%) Controls n(%) Adjusteda OR 
[95% CI]
PP interaction
XPC PAT XPD Lys751Gln
-/- Lys/Lys 72 (13.9) 84 (15.8) 1.00 (reference)
+/+ Lys/Lys 36 (7.0) 38 (7.1) 1.10 [0.59–2.06] 0.971
+/+ Lys/Gln 49 (9.5) 37 (6.9) 1.63 [0.89–2.98] 0.111
+/+ Gln/Gln 16 (3.1) 9 (1.7) 2.25 [0.83–6.13] 0.202 0.202
XPC PAT XRCC3 
Thr241Met
-/- Thr/Thr 49 (12.2) 60 (13.8) 1.00 (reference)
+/+ Thr/Thr 36 (8.9) 31 (7.1) 1.22 [0.61–2.43] 0.578
+/+ Thr/Met 34 (8.4) 27 (6.2) 1.41 [0.68–2.92] 0.351
+/+ Met/Met  12 (3.0) 6 (1.4) 3.06 [0.91–
10.30]
0.071 0.174
XPD Lys751Gln XRCC3 
Thr241Met
Lys/Lys Thr/Thr 83 (20.6) 89 (20.5) 1.00 (reference)
Gln/Gln Thr/Thr 17 (4.2) 17 (3.9) 0.98 [0.41–2.35] 0.968
Gln/Gln Thr/Met 20 (5.0) 18 (4.1) 1.59 [0.70–3.59] 0.264
Gln/Gln Met/Met  10 (2.5) 5 (1.2) 2.66 [0.74–9.62] 0.135 0.261
a Adjusted by age, gender and cumulative tobacco consumption (in pack-years: ≤ 16.45, > 16.45–53 and > 53)BMC Cancer 2007, 7:162 http://www.biomedcentral.com/1471-2407/7/162
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399Gln/Gln genotype showed a not significant increased
risk for light smokers, suggesting any kind of effect modi-
fication as Hung et al. concluded for all smoking related
cancers [74]. These results fit in studies showing 399Gln
allele may be associated with higher mutagen sensitivity
and higher levels of DNA adducts [75] who reported that
never smokers carriers of 399Gln had higher DNA adduct
levels than current smokers.
The XRCC3 241Met allele has previously been associated
with less efficient DNA repair [75], as well as an increased
number of centrosomes and binucleated cells [76]. How-
ever, it has also been shown that the common and the var-
iant  XRCC3  alleles are functionally equivalent in the
double-strand break repair pathway [77], which may
explain the lack of association between XRCC3
Thr241Met polymorphism and lung cancer risk shown in
several studies [41,42,47]. In the Caucasian population,
there are inconclusive and conflicting results: several stud-
ies have found an increased risk for non small cell carci-
noma and lung cancer [19,43], while other studies have
shown a protective effect, once more for non small cell
carcinoma and ever smokers [20,38]. Our study showed a
statistically significant protective effect for squamous cell
carcinoma, but it is difficult to assess the effect of this sin-
gle common sequence variant because it might not be
detectable in population association studies being neces-
sary larger samples.
We have found that polymorphisms in NER genes
increase the risk of developing lung cancer, while no asso-
ciation was found between polymorphisms in BER and
DSBR genes and lung cancer risk. These results might
reflect differences in the etiology of different carcinomas,
or a more important role of the NER repair pathways in
the development of lung cancer. In this regard, numerous
studies have shown that most DNA lesions caused by
tobacco-smoke carcinogens are repaired by the NER
mechanism [8,78,79], suggesting that this particular can-
cer could be more susceptible to polymorphisms affecting
genes implicated in the NER pathway.
Although the relative risks for individuals carrying the
polymorphisms in XPC and XPD genes are modest (ORs
< 1.52), these polymorphisms could account for a large
proportion of lung cancers, as they are very common in
the population. In fact, between 9% and 16% of individ-
uals are homozygous for the high-risk genotypes (XPC
PAT+/+ or XPD 751Gln/Gln). In this regard, we observed a
borderline combined effect between these polymor-
phisms and the risk of lung cancer, as individuals
homozygous for both risk genotypes showed a further
increase in the risk of developing lung cancer than that
observed for the individual polymorphisms (adjusted OR
= 2.25; 95% CI 0.83–6.13, P = 0.202). This combined
effect of XPC and XPD polymorphisms could support the
hypothesis for this population that changes in genes
implicated in the NER repair pathway contribute to the
susceptibility of developing lung cancer, and the combi-
nation of genotypes with a reduced ability to repair DNA
lesions could result in a higher risk of developing this dis-
ease.
Similarly, when we combined XRCC3 241Met/Met geno-
type with the XPC PAT+/+ or the XPD 751Gln/Gln geno-
types, an increased risk was observed (Table 5). These
results could suggest that the DSBR mechanism might
also play a role in the development of lung cancer when
combined with certain NER genes genotypes. Indeed,
smoking induces a great variety of DNA damage, which
must be repaired by more than one repair pathway, being
NER the main pathway and DSBR the second, thus the
combined occurrence of genetic variants in these two
repair pathways might contribute to a greater risk of lung
cancer. The approach of using combined analysis of poly-
morphisms may represent an alternative way of analyzing
the overall effect of the different genetic variants as well as
the potential joint effect of these genes.
Conclusion
In conclusion, we analysed the association between XPC,
XPD, XRCC1, and XRCC3 polymorphisms and the indi-
vidual susceptibility to develop lung cancer in the Spanish
population, specifically with a highly tobacco exposed
population. We attempt to contribute to the discovery of
which biomarkers of DNA repair capacity are useful for
screening high-risk populations for primary preventing
and early detection of lung cancer. To further evaluate
gene-gene and gene-environment interactions between
this polymorphisms and lung cancer risk in our popula-
tion, a single larger sample with thousands of subjects and
tissue-specific biochemical and biological characteriza-
tions are required. Finally, higher sample size will be also
required to confirm small associations and to evaluate
complex interrelationships between genetic variants and
smoking type and status.
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